1,141
Views
61
CrossRef citations to date
0
Altmetric
Review Article

The Immunoproteasome in oxidative stress, aging, and disease

, &
Pages 268-281 | Received 19 Feb 2016, Accepted 28 Mar 2016, Published online: 20 Apr 2016

References

  • Ahtoniemi T, Goldsteins G, Keksa-Goldsteine V, et al. (2007). Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol Pharmacol 71:30–7.
  • Aiken CT, Kaake RM, Wang X, Huang L. (2011). Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Prot 10:R110.
  • Aki M, Shimbara N, Takashina M, et al. (1994). Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem 115:257–69.
  • Akiyama K, Kagawa S, Tamura T, et al. (1994). Replacement of proteasome subunits X and Y by LMP7 and LMP2 induced by interferon-gamma for acquirement of the functional diversity responsible for antigen processing. FEBS Lett 343:85–8.
  • Angeles A, Fung G, Luo H. (2012). Immune and non-immune functions of the immunoproteasome. Front Biosci 17:1904–16.
  • Arima K, Kinoshita A, Mishima H, et al. (2011). Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci USA 108:14914–19.
  • Bar-Nun S, Glickman MH. (2012). Proteasomal AAA-ATPases: structure and function. Biochim Biophys Acta 1823:67–82.
  • Basler M, Kirk CJ, Groettrup M. (2013). The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 25:74–80.
  • Beatty S, Koh HH, Phil M, et al. (2000). The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45:115–34.
  • Beckman JS, Carson M, Smith CD, Koppenol WH. (1993). ALS, SOD and peroxynitrite. Nature 364:584–84.
  • BelardellI F. (1995). Role of interferons and other cytokines in the regulation of the immune response. APMIS 103:161–79.
  • Bierhaus A, Humpert PM, Morcos M, et al. (2005). Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876–86.
  • Bose S, Brooks P, Mason G, Rivett A. (2001). gamma-Interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation. Biochem J 353:291–7.
  • Brown MG, Driscoll J, Monaco JJ. (1991). Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353:355–57.
  • Bulteau AL, Lundberg KC, Humphries KM, et al. (2001). Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276:30057–63.
  • Chistyakov DA, Savost’anov KV, Turakulov RI, et al. (2000). Complex association analysis of Graves disease using a set of polymorphic markers. Mol Genet Metab 70:214–18.
  • Davies KJ. (2001). Degradation of oxidized proteins by the 20S proteasome. Biochimie 83:301–10.
  • Davies KJA. (1993). Protein modification by oxidants and the role of proteolytic enzymes. Biochem Soc Trans 21:346–53.
  • Davies KJA, Goldberg A. (1987). Proteins damaged by oxygen radicals are rapidly degraded in extracts of red blood cells. J Biol Chem 262:8227–34.
  • Demars R, Spies T. (1992). New genes in the MHC that encode proteins for antigen processing. Trends Cell Biol 2:81–6.
  • Deng GY, Muir A, Maclaren NK, She JX. (1995). Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Genet 56:528.
  • Díaz-Hernández M, Hernández F, Martín-Aparicio E, et al. (2003). Neuronal induction of the immunoproteasome in Huntington’s disease. J Neurosci 23:11653–61.
  • Ding Q, Martin S, Dimayuga E, et al. (2006). LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins. Antioxid Redox Signal 8:130–5.
  • Ding Q, Reinacker K, Dimayuga E, et al. (2003). Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. FEBS Lett 546:228–32.
  • Ermak G, Hench KJ, Chang KT, et al. (2009). Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro. J Biol Chem 284:11845–53.
  • Ermak G, Morgan TE, Davies KJA. (2001). Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer’s disease. J Biol Chem 276:38787–94.
  • Ethen CM, Hussong SA, Reilly C, et al. (2007). Transformation of the proteasome with age-related macular degeneration. FEBS Lett 581:885–90.
  • Evans M, Couch Y, Sibson N, Turner M. (2013). Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 53:34–41.
  • Fagan JM, Waxman L, Goldberg A. (1986). Red blood cells contain a pathway for the degradation of oxidant-damaged hemoglobin that does not require ATP or ubiquitin. J Biol Chem 261:5705–13.
  • Fellerhoff B, Gu S, Laumbacher B, et al. (2011). The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer. Cancer Res 71:7145–54.
  • Ferrington DA, Gregerson DS. (2012). Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci 109:75–112.
  • Ferrington DA, Husom AD, Thompson LV. (2005). Altered proteasome structure, function, and oxidation in aged muscle. FASEB J 19:644–6.
  • Ferrington DA, Hussong SA, Roehrich H, et al. (2008). Immunoproteasome responds to injury in the retina and brain. J Neurochem 106:158–69.
  • Foss GS, Prydz H. (1999). Interferon regulatory factor 1 mediates the interferon-γ induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1. J Biol Chem 274:35196–202.
  • Fraile A, Nieto A, Vinasco J, et al. (1998). Association of large molecular weight proteasome 7 gene polymorphism with ankylosing spondylitis. Arthritis Rheum 41:560–2.
  • Fratta P, Engel WK, Mcferrin J, et al. (2005). Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-β precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 167:517–26.
  • Früh K, Yang Y, Arnold D, et al. (1992). Alternative exon usage and processing of the major histocompatibility complex-encoded proteasome subunits. J Biol Chem 267:22131–40.
  • Gavilán MP, Castaño A, Torres M, et al. (2009). Age‐related increase in the immunoproteasome content in rat hippocampus: molecular and functional aspects. J Neurochem 108:260–72.
  • Giulivi C, Pacifici RE, Davies KJA. (1994). Exposure of hydrophobic moieties promotes the selective degradation of hydrogen peroxide-modified hemoglobin by the multicatalytic proteinase complex, proteasome. Arch Biochem Biophys 311:329–41.
  • Glickman MH, Ciechanover A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–28.
  • Goedert M, Spillantini M, Jakes R, et al. (1989). Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–26.
  • Goldberg AL, Cascio P, Saric T, Rock KL. (2002). The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147–64.
  • Gomes AV. (2013). Genetics of proteasome diseases. Scientifica 2013, 30 pages. Available from: http://www.hindawi.com.libproxy1.usc.edu/journals/scientifica/2013/637629/cta/
  • Griffin TA, Nandi D, Cruz M, et al. (1998). Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 187:97–104.
  • Grimm S, Ott C, Hörlacher M, et al. (2012). Advanced-glycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2/STAT1. Biochem J 448:127–39.
  • Groettrup M, Kraft R, Kostka S, et al. (1996). A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol 26:863–69.
  • Grune T, Botzen D, Engels M, et al. (2010). Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch Biochem Biophys 500:181–8.
  • Grune T, Catalgol B, Licht A, et al. (2011). HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radic Biol Med 51:1355–64.
  • Grune T, Jung T, Merker K, Davies KJ. (2004). Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ‘aggresomes’ during oxidative stress, aging, and disease. Int J Biochem Cell Biol 36:2519–30.
  • Gu ZC, Enenkel C. (2014). Proteasome assembly. Cell Mol Life Sci 71:4729–45.
  • Guillaume B, Chapiro J, Stroobant V, et al. (2010). Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci USA 107:18599–604.
  • Hardy J, Selkoe D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–6.
  • Hayashi M, Ishibashi T, Tanaka K, Kasahara M. (1997). The mouse genes encoding the third pair of beta-type proteasome subunits regulated reciprocally by IFN-gamma: structural comparison, chromosomal localization, and analysis of the promoter. J Immunol 159:2760–70.
  • Hayashi T, Horiuchi A, Sano K, et al. (2011). Molecular approach to uterine leiomyosarcoma: LMP2-deficient mice as an animal model of spontaneous uterine leiomyosarcoma. Sarcoma 2011, Article ID 476498, 6 pages.
  • Heink S, Ludwig D, Kloetzel PM, Krüger E. (2005). IFN-γ-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci USA 102:9241–6.
  • Hendil KB, Khan S, Tanaka K. (1998). Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem J 332:749–54.
  • Huber EM, Basler M, Schwab R, et al. (2012). Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148:727–38.
  • Husom AD, Peters EA, Kolling EA, et al. (2004). Altered proteasome function and subunit composition in aged muscle. Arch Biochem Biophys 421:67–76.
  • Hussong SA, Kapphahn RJ, Phillips SL, et al. (2010). Immunoproteasome deficiency alters retinal proteasome’s response to stress. J Neurochem 113:1481–90.
  • Jansen AH, Reits EA, Hol EM. (2014). The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. Front Mol Neurosci 7:73.
  • Jung T, Höhn A, Grune T. (2014). The proteasome and the degradation of oxidized proteins: part II – protein oxidation and proteasomal degradation. Redox Biol 2:99–104.
  • Karch CM, Goate AM. (2015). Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77:43–51.
  • Kästle M, Reeg S, Rogowska-Wrzesinska A, Grune T. (2012). Chaperones, but not oxidized proteins, are ubiquitinated after oxidative stress. Free Radic Biol Med 53:1468–77.
  • Keck S, Nitsch R, Grune T, Ullrich O. (2003). Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem 85:115–22.
  • Khan MA, Oubrahim H, Stadtman ER. (2004). Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome. Proc Natl Acad Sci USA 101:11560–5.
  • Kitamura A, Maekawa Y, Uehara H, et al. (2011). A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Investig 121:4150–60.
  • Kniepert A, Groettrup M. (2014). The unique functions of tissue-specific proteasomes. Trends Biochem Sci 39:17–24.
  • Kotamraju S, Kalivendi S, Shang T, Kalyanaraman B. (2005). Nitric oxide, proteasomal function, and iron homeostasis-implications in aging and neurodegenerative diseases. Meth Enzymol 396:526–34.
  • Kotamraju S, Matalon S, Matsunaga T, et al. (2006). Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Rad Biol Med 40:1034–44.
  • Kotamraju S, Tampo Y, Keszler A, et al. (2003). Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: role of ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 100:10653–8.
  • Krüger E, Kloetzel PM. (2012). Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme. Curr Opin Immunol 24:77–83.
  • Le Bourg É. (2007). Hormetic effects on longevity of hydrogen peroxide in Drosophila melanogaster flies living on a poorly nutritious medium. Biogerontology 8:327–44.
  • Leroy E, Boyer R, Auburger G, et al. (1998). The ubiquitin pathway in Parkinson’s disease. Nature 395:451–2.
  • Liu Y, Ramot Y, Torrelo A, et al. (2012). Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64:895–907.
  • Lloret A, Badia MC, Giraldo E, et al. (2011). Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer’s disease. J Alzheimers Dis 27:701–9.
  • Lowenstein CJ, Padalko E. (2004). iNOS (NOS2) at a glance. J Cell Sci 117:2865–7.
  • Ma X, Yang C, Tang R, et al. (2015). Association between LMP2 and LMP7 gene polymorphisms and the risk of gastric cancer: a case-control study. Oncol Lett 10:509–17.
  • Maksymowych WP, Suarez-Almazor M, Chou CT, Russell A. (1995). Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis. Ann Rheum Dis 54:321–4.
  • Mccarthy MK, Weinberg JB. (2015). The immunoproteasome and viral infection: a complex regulator of inflammation. Front Microbiol 6, 21 pages.
  • Meissner F, Molawi K, Zychlinsky A. (2010). Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci USA 107:13046–50.
  • Mishto M, Bellavista E, Santoro A, et al. (2006). Immunoproteasome and LMP2 polymorphism in aged and Alzheimer’s disease brains. Neurobiol Aging 27:54–66.
  • Morgan MJ, Liu ZG. (2011). Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 21:103–15.
  • Muchamuel T, Basler M, Aujay MA, et al. (2009). A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15:781–7.
  • Neuman KM, Molina-Campos E, Musial TF, et al. (2015). Evidence for Alzheimer’s disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. Brain Struct Funct 220:3143–65.
  • Ortiz-Navarrete V, Seelig A, Gernold M, et al. (1991). Subunit of the ‘20S’ proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 353:662–4.
  • Pacher P, Beckman JS, Liaudet L. (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315–424.
  • Pacifici R, Kono Y, Davies KJA. (1993). Hydrophobicity as the signal for selective degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase complex, proteasome. J Biol Chem 268:15405–11.
  • Pacifici RE, Salo DC, Davies KJA. (1989). Macroxyproteinase (MOP): a 670 kDa proteinase complex that degrades oxidatively denatured proteins in red blood cells. Free Rad Biol Med 7:521–36.
  • Pearl-Yafe M, Halperin D, Halevy A, et al. (2003). An oxidative mechanism of interferon induced priming of the Fas pathway in Fanconi anemia cells. Biochem Pharmacol 65:833–42.
  • Pickering A, Koop A, Teoh C, et al. (2010). The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem J 432:585–94.
  • Pickering AM, Davies KJA. (2012a). Degradation of damaged proteins: the main function of the 20S proteasome. Prog Mol Biol Transl Sci 109:227–48.
  • Pickering AM, Davies KJA. (2012b). Differential roles of proteasome and immunoproteasome regulators Pa28αβ, Pa28γ and Pa200 in the degradation of oxidized proteins. Arch Biochem Biophys 523:181–90.
  • Pickering AM, Lehr M, Miller RA. (2015). Lifespan of mice and primates correlates with immunoproteasome expression. J Clin Investig 125:2059–68.
  • Pickering AM, Linder RA, Zhang H, et al. (2012). Nrf2-dependent induction of proteasome and Pa28αβ regulator are required for adaptation to oxidative stress. J Biol Chem 287:10021–31.
  • Pickering AM, Staab TA, Tower J, et al. (2013a). A conserved role for the 20S proteasome and Nrf2 transcription factor in oxidative stress adaptation in mammals, Caenorhabditis elegans and Drosophila melanogaster. J Exp Biol 216:543–53.
  • Pickering AM, Vojtovich L, Tower J, DAVIES KJA. (2013b). Oxidative stress adaptation with acute, chronic, and repeated stress. Free Radic Biol Med 55:109–18.
  • Planas R, Carrillo J, Sanchez A, et al. (2010). Gene expression profiles for the human pancreas and purified islets in Type 1 diabetes: new findings at clinical onset and in long-standing diabetes. Clin Exp Immunol 159:23–44.
  • Poppek D, Keck S, Ermak G, et al. (2006). Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem J 400:511–20.
  • Powell SR, Wang P, Divald A, et al. (2005). Aggregates of oxidized proteins (lipofuscin) induce apoptosis through proteasome inhibition and dysregulation of proapoptotic proteins. Free Rad Biol Med 38:1093–101.
  • Puttaparthi K, Elliott JL. (2005). Non-neuronal induction of immunoproteasome subunits in an ALS model: possible mediation by cytokines. Exp Neurol 196:441–51.
  • Reinheckel T, Sitte N, Ullrich O, et al. (1998). Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 335:637–42.
  • Rivett AJ, Bose S, Brooks P, Broadfoot KI. (2001). Regulation of proteasome complexes by γ-interferon and phosphorylation. Biochimie 83:363–6.
  • Rockwell CE, Monaco JJ, Qureshi N. (2012). A critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes. Pharmacology 89:117–26.
  • Schwarz KB. (1996). Oxidative stress during viral infection: a review. Free Radic Biol Med 21:641–9.
  • Seifert U, Bialy LP, Ebstein F, et al. (2010). Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142:613–24.
  • Semchyshyn HM. (2014). Hormetic concentrations of hydrogen peroxide but not ethanol induce cross-adaptation to different stresses in budding yeast. Int J Microbiol 2014, Article ID 485792, 5 pages.
  • Shang F, Taylor A. (1995). Oxidative stress and recovery from oxidative stress are associated with altered ubiquitin conjugating and proteolytic activities in bovine lens epithelial cells. Biochem J 307:297–303.
  • Shringarpure R, Grune T, Mehlhase J, Davies KJ. (2003). Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 278:311–18.
  • Sitte N, Huber M, Grune T, et al. (2000a). Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. FASEB J 14:1490–8.
  • Sitte N, Merker K, von Zglinicki T, et al. (2000b). Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part II—aging of nondividing cells. FASEB J 14:2503–10.
  • Sitte N, Merker K, von Zglinicki T, et al. (2000c). Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I—effects of proliferative senescence. FASEB J 14:2495–502.
  • Stadtman ER. (2006). Protein oxidation and aging. Free Rad Res 40:1250–8.
  • Stratford FL, Chondrogianni N, Trougakos IP, et al. (2006). Proteasome response to interferon-gamma is altered in senescent human fibroblasts . FEBS Lett 580:3989–94.
  • Takada Y, Mukhopadhyay A, Kundu GC, et al. (2003). Hydrogen peroxide activates NF-κB through tyrosine phosphorylation of IκBα and serine phosphorylation of p65 evidence for the involvement of IκBα kinase and Syk protein-tyrosine kinase. J Biol Chem 278:24233–41.
  • Tanahashi N, Murakami Y, Minami Y, et al. (2000). Hybrid proteasomes: induction by interferon-γ and contribution to ATP-dependent proteolysis. J Biol Chem 275:14336–45.
  • Tanoka K, Kasahara M. (1998). The MHC class I ligand‐generating system: roles of immunoproteasomes and the interferon‐4gMY‐inducible proteasome activator PA28. Immunol Rev 163:161–76.
  • Teoh CY, Davies KJA. (2004). Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation: the ‘PrOxI’ hypothesis. Arch Biochem Biophys 423:88–96.
  • Thomas S, Kotamraju S, Zielonka J, et al. (2007). Hydrogen peroxide induces nitric oxide and proteosome activity in endothelial cells: a bell-shaped signaling response. Free Rad Biol Med 42:1049–61.
  • Vilchez D, Saez I, Dillin A. (2014). The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun 5.
  • Vitek MP, Bhattacharya K, Glendening JM, et al. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91:4766–70.
  • Wang X, Yen J, Kaiser P, Huang L. (2010). Regulation of the 26S proteasome complex during oxidative stress. Sci Signal 3:ra88.
  • Watanabe Y, Suzuki O, Haruyama T, Akaike T. (2003). Interferon‐γ induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. J Cell Biochem 89:244–53.
  • Whalley K. (2015). Neurodegenerative disease: restoring balance in Huntington disease. Nat Rev Neurosci 16:66–7.
  • Yu Z, Liu Q, Huang C, et al. (2013). The interleukin 10-819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. Omics 17:200–14.
  • Yun YS, Kim KH, Tschida B, et al. (2016). mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress. Mol Cell 61:625–39.
  • Zhou P, Cao H, Smart M, David C. (1993). Molecular basis of genetic polymorphism in major histocompatibility complex-linked proteasome gene (Lmp-2). Proc Natl Acad Sci USA 90:2681–4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.